Allergan/ISTA Vitrase review
Executive Summary
FDA's Dermatologic & Ophthalmic Drugs Advisory Committee will review ISTA's Vitrase (ovine hyaluronidase) for treatment of vitreous hemorrhage on March 17. ISTA began the rolling NDA for Vitrase in January 2002. Under an agreement with ISTA, Allergan will be responsible for sales and marketing. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m...